Young-Hwa Chung Selected Research

clevudine

3/2011	Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy.
10/2007	Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.
5/2007	Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.
1/2007	Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy.
5/2006	A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Young-Hwa Chung Research Topics

Disease

53	Hepatocellular Carcinoma (Hepatoma) 11/2022 - 01/2002
42	Neoplasms (Cancer) 12/2022 - 01/2002
21	Chronic Hepatitis B 08/2014 - 05/2003
13	Infections 01/2016 - 05/2002
12	Fibrosis (Cirrhosis) 11/2018 - 12/2002
9	Lung Neoplasms (Lung Cancer) 01/2019 - 01/2013
7	Colonic Neoplasms (Colon Cancer) 06/2019 - 04/2009
6	Lymphoma (Lymphomas) 01/2016 - 06/2004
6	Liver Diseases (Liver Disease) 11/2011 - 10/2005
5	Carcinogenesis 01/2020 - 04/2009
5	Neoplasm Metastasis (Metastasis) 11/2016 - 08/2009
5	Hepatitis B 01/2016 - 01/2010
5	Liver Neoplasms (Liver Cancer) 12/2015 - 06/2011
5	Hepatitis 06/2013 - 03/2002
4	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 01/2002
4	Thrombosis (Thrombus) 03/2015 - 11/2002
4	Chronic Hepatitis (Chronic Active Hepatitis) 12/2010 - 05/2003
3	Hepatic Encephalopathy 01/2020 - 12/2002
3	Non-alcoholic Fatty Liver Disease 11/2015 - 05/2010
3	End Stage Liver Disease 08/2015 - 10/2005
3	Hypoxia (Hypoxemia) 05/2015 - 03/2008
3	Pancreatic Neoplasms (Pancreatic Cancer) 05/2015 - 02/2011
3	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 05/2014 - 06/2011
3	Disease Progression 10/2012 - 12/2006
2	Carcinoma (Carcinomatosis) 02/2022 - 11/2014
2	Hemorrhage 01/2022 - 12/2002
2	Esophageal and Gastric Varices (Esophageal Varices) 01/2022 - 12/2002
2	Parkinson Disease (Parkinson's Disease) 01/2019 - 11/2012
2	Virus Diseases (Viral Diseases) 05/2015 - 12/2010
2	Inflammation (Inflammations) 01/2014 - 12/2007
2	Adenocarcinoma 06/2012 - 02/2011
2	Melanoma (Melanoma, Malignant) 04/2011 - 09/2010
2	Reoviridae Infections 04/2010 - 09/2009
2	Kaposi Sarcoma (Kaposi's Sarcoma) 05/2002 - 05/2002

Drug/Important Bio-Agent (IBA)

23	Proteins (Proteins, Gene)FDA Link 12/2022 - 05/2002
14	Lamivudine (Epivir)FDA Link 01/2016 - 03/2002
11	CateninsIBA 01/2020 - 08/2009
9	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 05/2003
9	Hepatitis B e AntigensIBA 08/2014 - 02/2004
8	Alanine Transaminase (SGPT)IBA 11/2022 - 02/2004
8	Antiviral Agents (Antivirals)IBA 01/2016 - 05/2006
7	alpha-Fetoproteins (alpha-Fetoprotein)IBA 04/2013 - 01/2002
6	Sorafenib (BAY 43-9006)FDA Link 07/2020 - 01/2013
5	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2022 - 07/2012
5	CytokinesIBA 01/2018 - 05/2002
5	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2018 - 05/2003
5	Cyclin D1IBA 05/2017 - 08/2009
5	Neoplasm Antigens (Tumor Antigens)IBA 12/2014 - 03/2008
5	InterferonsIBA 06/2013 - 05/2003
5	clevudineIBA 03/2011 - 05/2006
4	Small Interfering RNA (siRNA)IBA 01/2020 - 06/2012
4	Pharmaceutical PreparationsIBA 01/2019 - 01/2014
4	entecavir FDA Link 01/2016 - 10/2009
4	Fetal Proteins (Fetoprotein)IBA 12/2015 - 11/2011
4	Oncogene Proteins (Oncogene Protein)IBA 07/2014 - 02/2007
4	Sirtuin 1IBA 01/2014 - 06/2012
4	Ethiodized Oil (Ethiodol)FDA Link 06/2013 - 01/2002
4	adefovir dipivoxil (Hepsera)FDA Link 02/2012 - 10/2005
4	lipoarabinomannan (LAM)IBA 02/2012 - 12/2004
4	adefovirIBA 09/2010 - 06/2006
3	Messenger RNA (mRNA)IBA 02/2022 - 01/2002
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 01/2016
3	TCF Transcription FactorsIBA 05/2017 - 06/2011
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2015 - 04/2010
3	Etoposide (VP 16)FDA LinkGeneric 03/2015 - 01/2014
3	beta CateninIBA 09/2009 - 04/2009
3	Transforming Growth Factor beta1 (TGF beta 1)IBA 02/2009 - 01/2002
2	RNA (Ribonucleic Acid)IBA 11/2022 - 01/2018
2	Serum AlbuminIBA 10/2021 - 12/2015
2	Phosphotransferases (Kinase)IBA 01/2020 - 11/2012
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 12/2017
2	3-(3,4-dihydroxy-phenyl)-acrylic acid 2,2- dimethyl- 8- oxo- 3,4- dihydro- 2H,8H- pyrano(3,2- g)chromen- 3- yl- esterIBA 01/2019 - 01/2012
2	xanthoneIBA 01/2019 - 01/2018
2	Antineoplastic Agents (Antineoplastics)IBA 12/2018 - 03/2002
2	A Kinase Anchor ProteinsIBA 11/2018 - 01/2018
2	CholesterolIBA 01/2018 - 08/2012
2	Transcription Factors (Transcription Factor)IBA 05/2015 - 04/2011
2	Pemetrexed (MTA)FDA Link 12/2014 - 08/2009
2	hepatitis B virus X proteinIBA 07/2014 - 12/2012
2	ResveratrolIBA 07/2012 - 06/2012
2	HLA-DRB1 Chains (HLA DRB1)IBA 05/2012 - 01/2011
2	HLA Antigens (Human Leukocyte Antigens)IBA 05/2012 - 01/2011
2	AntigensIBA 03/2012 - 03/2011
2	Transforming Growth Factor beta (TGF-beta)IBA 01/2012 - 02/2009
2	ElafinIBA 04/2011 - 09/2010
2	Immunoglobulins (Immunoglobulin)IBA 04/2011 - 01/2010
2	Ribavirin (Virazole)FDA LinkGeneric 06/2010 - 12/2007
2	Serine (L-Serine)FDA Link 08/2009 - 10/2008
2	Anti-Bacterial Agents (Antibiotics)IBA 04/2009 - 08/2003
2	Tamoxifen FDA LinkGeneric 02/2009 - 03/2003
1	Pyruvate KinaseIBA 02/2022

Therapy/Procedure

29	Therapeutics 01/2018 - 03/2002
7	Liver Transplantation 01/2020 - 12/2007
6	Radiotherapy 01/2018 - 06/2007
5	Drug Therapy (Chemotherapy) 01/2018 - 04/2010
4	Hepatectomy 01/2020 - 03/2010
2	Transplantation 01/2019 - 01/2013
2	Radiofrequency Ablation 12/2015 - 12/2013
2	Aftercare (After-Treatment) 05/2015 - 11/2002
2	Surgical Portasystemic Shunt (Portosystemic Shunt) 03/2008 - 12/2002